A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
about
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
description
clinical trial
@en
klinisch onderzoek
@nl
name
A Study Evaluating Talazoparib ...... BRCA Mutation (EMBRACA Study)
@en
type
label
A Study Evaluating Talazoparib ...... BRCA Mutation (EMBRACA Study)
@en
prefLabel
A Study Evaluating Talazoparib ...... BRCA Mutation (EMBRACA Study)
@en
P17
P6153
P1476
A PHASE 3, OPEN-LABEL, RANDOMI ...... EGIMENS FOR METASTATIC DISEASE
@en
P17
P1813
EMBRACA
@en
P3098
NCT01945775
P580
2013-10-14T00:00:00Z
P582
2017-09-15T00:00:00Z